Details
Stereochemistry | ACHIRAL |
Molecular Formula | C32H38N4O6S |
Molecular Weight | 606.732 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC2=C(C=C1)C3=C(C4CCCCC4)C5=C6C=C(C=C5)C(=O)NS(=O)(=O)N(C)CCOCCN(C)C(=O)C(CN36)=C2
InChI
InChIKey=UOBYJVFBFSLCTQ-UHFFFAOYSA-N
InChI=1S/C32H38N4O6S/c1-34-13-15-42-16-14-35(2)43(39,40)33-31(37)22-9-11-27-28(19-22)36-20-24(32(34)38)17-23-18-25(41-3)10-12-26(23)30(36)29(27)21-7-5-4-6-8-21/h9-12,17-19,21H,4-8,13-16,20H2,1-3H3,(H,33,37)
Molecular Formula | C32H38N4O6S |
Molecular Weight | 606.732 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://adisinsight.springer.com/drugs/800033015Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/22710121
Sources: http://adisinsight.springer.com/drugs/800033015
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/22710121
TMC647055 is a potent and selective nonnucleoside inhibitor of NS5B binding site 1 (NNI-1) with activity against most HCV genotypes. Binding of inhibitors to NNI-1 is purported to displace the flexible λ1 loop from its thumb domain binding site, perturbing the interaction between the NS5B polymerase finger and thumb domains and thereby locking the enzyme in an open inactive conformation. Janssen R&D Ireland (formerly Tibotec Pharmaceuticals) is developing TMC 647055 as an oral once-daily treatment for chronic hepatitis C virus infections. Phase II development is underway in Belgium, Germany and the US.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL5375 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22710121 |
4.1 nM [Kd] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no | ||||
yes | yes (expression study) Comment: The plasma concentrations of 4-β-hydroxycholesterol, the endogenous biomarker for CYP3A4 induction, increased with increasing TMC647055 dose in healthy volunteers. Sources: https://pubs.acs.org/doi/abs/10.1021/jm401396p |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no | ||||
yes |
Sample Use Guides
In Vivo Use Guide
Sources: http://adisinsight.springer.com/drugs/800033015
A phase I trial assessed the safety and tolerability of TMC 647055 administered as an oral solution for 6 days in increasing single doses from 100 mg to 3000 mg in fed conditions and in multiple oral doses (NCT01202825)
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22710121
The frequency of resistant colony formation was determined in a colony formation assay using wild-type HCV genotype 1b replicon (Huh7-Luc) cells incubated in the presence of different concentrations of TMC647055, no resistant replicon cell colonies were observed with 1.5 μM TMC647055 alone, indicating complete clearance of the replicon from the cells.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 02:20:14 GMT 2023
by
admin
on
Sat Dec 16 02:20:14 GMT 2023
|
Record UNII |
11BD024G7J
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1204416-97-6
Created by
admin on Sat Dec 16 02:20:14 GMT 2023 , Edited by admin on Sat Dec 16 02:20:14 GMT 2023
|
PRIMARY | |||
|
44556044
Created by
admin on Sat Dec 16 02:20:14 GMT 2023 , Edited by admin on Sat Dec 16 02:20:14 GMT 2023
|
PRIMARY | |||
|
11BD024G7J
Created by
admin on Sat Dec 16 02:20:14 GMT 2023 , Edited by admin on Sat Dec 16 02:20:14 GMT 2023
|
PRIMARY | |||
|
DTXSID90152860
Created by
admin on Sat Dec 16 02:20:14 GMT 2023 , Edited by admin on Sat Dec 16 02:20:14 GMT 2023
|
PRIMARY | |||
|
DB11822
Created by
admin on Sat Dec 16 02:20:14 GMT 2023 , Edited by admin on Sat Dec 16 02:20:14 GMT 2023
|
PRIMARY | |||
|
TMC-647055
Created by
admin on Sat Dec 16 02:20:14 GMT 2023 , Edited by admin on Sat Dec 16 02:20:14 GMT 2023
|
PRIMARY |